Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Correction

Correction to: TRIM29 facilitates the epithelial-tomesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/β-catenin signaling pathway

Authors: Juntao Sun, Tianyu Zhang, Mengmeng Cheng, Liwen Hong, Chen Zhang, Mengfan Xie, Peijun Sun, Rong Fan, Zhengting Wang, Lei Wang, Jie Zhong

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Excerpt

Correction to: J Exp Clin Cancer Res 38, 104 (2019)
Literature
Metadata
Title
Correction to: TRIM29 facilitates the epithelial-tomesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/β-catenin signaling pathway
Authors
Juntao Sun
Tianyu Zhang
Mengmeng Cheng
Liwen Hong
Chen Zhang
Mengfan Xie
Peijun Sun
Rong Fan
Zhengting Wang
Lei Wang
Jie Zhong
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-01922-w

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine